TW279866B - - Google Patents

Info

Publication number
TW279866B
TW279866B TW083104441A TW83104441A TW279866B TW 279866 B TW279866 B TW 279866B TW 083104441 A TW083104441 A TW 083104441A TW 83104441 A TW83104441 A TW 83104441A TW 279866 B TW279866 B TW 279866B
Authority
TW
Taiwan
Application number
TW083104441A
Other languages
Chinese (zh)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of TW279866B publication Critical patent/TW279866B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
TW083104441A 1993-05-21 1994-05-17 TW279866B (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939310635A GB9310635D0 (en) 1993-05-21 1993-05-21 Chemical compounds

Publications (1)

Publication Number Publication Date
TW279866B true TW279866B (no) 1996-07-01

Family

ID=10736007

Family Applications (1)

Application Number Title Priority Date Filing Date
TW083104441A TW279866B (no) 1993-05-21 1994-05-17

Country Status (19)

Country Link
EP (1) EP0699196A1 (no)
JP (1) JPH08510455A (no)
CN (1) CN1126473A (no)
AU (1) AU6928794A (no)
BG (1) BG100154A (no)
CA (1) CA2162921A1 (no)
CZ (1) CZ305195A3 (no)
FI (1) FI955587A (no)
GB (1) GB9310635D0 (no)
HU (1) HUT73790A (no)
IL (1) IL109703A0 (no)
NO (1) NO954681D0 (no)
OA (1) OA10195A (no)
PE (1) PE31195A1 (no)
PL (1) PL311702A1 (no)
SK (1) SK142495A3 (no)
TW (1) TW279866B (no)
WO (1) WO1994027989A1 (no)
ZA (1) ZA943494B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT75871A (en) * 1993-09-30 1997-05-28 Yamanouchi Co Azole derivatives and pharmaceutical compositions thereof
AU3846395A (en) * 1994-11-07 1996-05-31 Janssen Pharmaceutica N.V. Compositions comprising carbazoles and cyclodextrins
CN1177350A (zh) * 1995-03-01 1998-03-25 山之内制药株式会社 咪唑衍生物及其药学组合物
CN1251577A (zh) * 1997-02-21 2000-04-26 武田药品工业株式会社 稠环化合物及其生产和应用
CN100572363C (zh) 2000-11-17 2009-12-23 武田药品工业株式会社 咪唑衍生物、其制备方法及其用途
ATE502030T1 (de) 2000-11-20 2011-04-15 Takeda Pharmaceutical Imidazolderivate, verfahren zu deren herstellung und deren verwendung
DE60139639D1 (de) 2000-12-08 2009-10-01 Takeda Pharmaceutical Substituierte thiazolderivate mit 3-pyridylgruppen, verfahren zu deren herstellung und deren verwendung
EP1902026B1 (en) 2005-06-24 2010-02-17 Eli Lilly And Company Tetrahydrocarbazole derivatives useful as androgen receptor modulators (sarm)
US8093279B2 (en) 2005-12-13 2012-01-10 Gillian Reed, legal representative Compound
GB0525323D0 (en) * 2005-12-13 2006-01-18 Sterix Ltd Compound
CN100586932C (zh) * 2007-01-26 2010-02-03 中国医学科学院医药生物技术研究所 抗肿瘤化合物及其制备方法
UA105794C2 (uk) 2009-06-26 2014-06-25 Новартіс Аг 1,3-ДИЗАМІЩЕНІ ПОХІДНІ ІМІДАЗОЛІДИН-2-ОНУ ЯК ІНГІБІТОРИ Cyp17
AU2011212813B2 (en) * 2010-02-04 2014-10-23 Radius Health, Inc. Selective androgen receptor modulators
ME02474B (me) 2010-05-12 2017-02-20 Radius Health Inc Terapijski režimi
US9132105B2 (en) 2010-08-04 2015-09-15 Pellficure Pharmaceuticals, Inc. Treatment of prostate carcinoma
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
EP2621901B1 (en) 2010-09-28 2015-07-29 Radius Health, Inc Selective androgen receptor modulators
ES2656218T3 (es) 2011-04-28 2018-02-26 Novartis Ag Inhibidores de 17 alfa-hidroxilasa/C17,20-liasa
US9492460B2 (en) * 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
CA2902335C (en) 2013-03-14 2021-09-14 Pellficure Pharmaceuticals, Inc. Novel therapy for prostate carcinoma
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
DK3122426T3 (da) 2014-03-28 2023-04-03 Univ Duke Behandling af brystcancer ved anvendelse af selektive østrogenreceptormodulatorer
US10093620B2 (en) 2014-09-12 2018-10-09 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
LT3474841T (lt) 2016-06-22 2022-06-10 Ellipses Pharma Ltd Ar+ krūties vėžio gydymo būdai
EP3528799A1 (en) 2016-10-24 2019-08-28 Pellficure Pharmaceuticals, Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione
PL3565542T3 (pl) 2017-01-05 2024-07-29 Radius Pharmaceuticals, Inc. Postacie polimorficzne rad1901-2hcl

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS229934B2 (en) * 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
GB8518743D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds

Also Published As

Publication number Publication date
BG100154A (en) 1996-07-31
OA10195A (en) 1996-12-18
PE31195A1 (es) 1995-10-18
AU6928794A (en) 1994-12-20
PL311702A1 (en) 1996-03-04
CN1126473A (zh) 1996-07-10
ZA943494B (en) 1995-01-23
FI955587A0 (fi) 1995-11-20
NO954681L (no) 1995-11-20
GB9310635D0 (en) 1993-07-07
JPH08510455A (ja) 1996-11-05
EP0699196A1 (en) 1996-03-06
IL109703A0 (en) 1994-08-26
FI955587A (fi) 1995-11-20
WO1994027989A1 (en) 1994-12-08
HUT73790A (en) 1996-09-30
SK142495A3 (en) 1996-06-05
NO954681D0 (no) 1995-11-20
CZ305195A3 (en) 1996-06-12
CA2162921A1 (en) 1994-12-08
HU9503321D0 (en) 1996-01-29

Similar Documents

Publication Publication Date Title
EP0636970A3 (no)
IN184938B (no)
TW280778B (no)
EP0714291A4 (no)
EP0643122A3 (no)
TW279866B (no)
FR2713711B1 (no)
FR2706989B1 (no)
FR2706919B3 (no)
EP0661252A3 (no)
IN176369B (no)
IN185940B (no)
IN176917B (no)
IN175910B (no)
ECSDI930131S (no)
ECSDI930158S (no)
IN175909B (no)
IN181200B (no)
ECSMU930026U (no)
DK102793D0 (no)
IN177795B (no)
ECSMU930025U (no)
IN181547B (no)
IN177165B (no)
IN174407B (no)